No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility
Description
As new data analysis adds weight to calls for retraction of a paper on paroxetine in adolescents, the author examines the resistance to action of a professional society, its journal, and an Ivy League universityCitation
Doshi, P. (2015). No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about insitutional responsibility. BMJ, 351. DOI: 10.1136/bmj.h4629Keyword
Restoring Invisible and Abandoned TrialsRIAT
Study 329
Clinical Trials as Topic--ethics
Conflict of Interest
Drug Industry--ethics
Paroxetine
Ethics, Institutional
Drug Evaluation--ethics
American Academy of Child and Adolescent Psychiatry
Brown University
GlaxoSmithKline
Pharmaceutical industry--Corrupt practices
Identifier to cite or link to this item
http://hdl.handle.net/10713/6591ae974a485f413a2113503eed53cd6c53
10.1136/bmj.h4629
Scopus Count
Collections
Related articles
- Putting GlaxoSmithKline to the test over paroxetine.
- Authors: Doshi P
- Issue date: 2013 Nov 12
- Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
- Authors: Hwang JP, Yang CH, Tsai SJ
- Issue date: 2004 Feb
- Odd odds.
- Authors: Andrade C
- Issue date: 2011 Nov
- Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women.
- Authors: Mück-Seler D, Sagud M, Mihaljevi-Peles A, Jakovljevi M, Pivac N
- Issue date: 2011 Jun
- Paroxetine and Study 329: what we already knew and when.
- Authors: Sasich LD
- Issue date: 2015 Oct 14